Experimental T-Cell Therapy Shows Promise Against Treatment-Resistant Cancers

(PHOTO: RITA ELENA SERDA)

The experimental treatment, known as invikafusp alfa, or invika, is being investigated for patients with advanced solid tumours, including cancers that have not responded successfully to standard immunotherapy.

The findings were announced by the NIH on October 23, 2026, following a clinical trial led by researchers from the National Cancer Institute, Mass General Brigham and Memorial Sloan Kettering.

A More Targeted Approach to Cancer Treatment

The experimental therapy is designed to stimulate selected populations of T cells, which are important components of the body's immune defence system.

Unlike approaches that broadly activate immune cells, invika is intended to stimulate specific tumour-infiltrating T-cell populations.

Researchers hope this targeted approach could encourage the immune system to attack cancer cells while reducing unwanted immune-related side effects.

Early Clinical Trial Results

The initial Phase 1 and Phase 2 findings showed promising signs of activity.

Among 27 participants treated at the selected optimal dose:

• 16 patients, approximately 59.3%, experienced no disease progression during the reported assessment.

• Four patients experienced reductions of more than 30% in the size of targeted tumours.

• Some participants had cancers that had previously resisted multiple treatments.

Researchers also observed that the treatment stimulated the targeted T-cell populations.

However, these findings represent early clinical evidence, not proof that the treatment is effective for all cancer patients.

What Happens Next?

Further clinical investigation will be necessary to determine the treatment's effectiveness, long-term safety and potential role alongside existing cancer therapies.

The research team is also exploring whether combining invika with other cancer treatments could improve patient outcomes.

The treatment has received FDA Fast Track designation for certain advanced solid tumours, which is intended to facilitate its development and review. This designation does not mean the drug has been approved for general cancer treatment.

A Potential New Direction in Immunotherapy

Cancer immunotherapy has transformed treatment options for  several types of cancer, but some tumours develop resistance or fail to respond.

Researchers believe more selective immune-cell activation could provide another direction for treating difficult-to-manage cancers.

Although further trials are required, the results offer an encouraging research development for patients with limited treatment options.